Results 131 to 140 of about 51,702 (211)

Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies. [PDF]

Neurotherapeutics
Albelo-Martínez M, Rizvi S.
europepmc   +1 more source

Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis. [PDF]

Mult Scler Relat Disord
Abdelhak A, Antweiler K, Kowarik MC, Senel M, Havla J, Zettl UK, Kleiter I, Hoshi MM, Skripuletz T, Haarmann A, Stahmann A, Huss A, Gingele S, Krumbholz M, Selge C, Friede T, Ludolph AC, Overell J, Koendgen H, Clinch S, Wang Q, Ziemann U, Hauser SL, Kümpfel T, Green AJ, Tumani H.   +25 more
europepmc   +1 more source

Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. [PDF]

Neurotherapeutics, 2022
Havla J, Hohlfeld R.
europepmc   +1 more source

Assessing Peripheral Blood Biomarkers and Predictive Patterns in Multiple Sclerosis Using Cytokines and Immune Gene Expression Profiles in Ocrelizumab-Treated Patients: Tracking Tumor Necrosis Factor. [PDF]

Int J Mol Sci
Jevtić B, Momcilovic N, Stegnjaić G, Lazarević M, Stanisavljević S, Tamas O, Veselinovic N, Budimkic M, Mesaros S, Miljković Đ, Pekmezovic T, Drulovic J, Nikolovski N.   +12 more
europepmc   +1 more source

Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review. [PDF]

Ann Clin Transl Neurol, 2023
Montalban X, Matthews PM, Simpson A, Petrie JL, Sammon C, Ramagopalan S, Disanto G, Kuhle J.   +7 more
europepmc   +1 more source

London Mozartiana: Wolfgang’s disputed age & early performances of Allegri’s Miserere [PDF]

, 2010
Chrissochoidis, I.
core  

Ocrelizumab: A Review in Multiple Sclerosis. [PDF]

Drugs, 2022
Lamb YN.
europepmc   +1 more source

A data-driven model of disability progression in progressive multiple sclerosis. [PDF]

Brain Commun
Garbarino S, Tur C, Lorenzi M, Pardini M, Piana M, Uccelli A, Arnold DL, Cree BAC, Sormani MP, Bovis F.   +9 more
europepmc   +1 more source

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. [PDF]

Neurology, 2021
Hauser SL, Kappos L, Montalban X, Craveiro L, Chognot C, Hughes R, Koendgen H, Pasquarelli N, Pradhan A, Prajapati K, Wolinsky JS.   +10 more
europepmc   +1 more source

Selecting Informative Patients for Phase 2 Progressive Trials in MS: Design Considerations for Phase 2 Clinical Trials in Progressive MS. [PDF]

Mult Scler
Koch MW, Camara-Lemarroy C, Strijbis E, Mostert J, Leavitt VM, Repovic P, Bowen JD, Comtois J, Uitdehaag B, Cutter G.   +9 more
europepmc   +1 more source